Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | ARG2 | P78540 | 4/20 | 0.43 |
| ▸ | ARG1 | P05089 | 3/20 | 0.43 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411132 | 1.00 | OTC (0.54) | OTCTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL31207026 | 0.89 | OTC (0.53) | OTCTP53SMN1; SMN2ALDH1A1GSR | |
| SCHEMBL29128940 | 0.89 | OTC (0.53) | OTCTP53SMN1; SMN2ALDH1A1GSR | |
| SCHEMBL18350239 | 0.88 | OTC (0.58) | OTCGSRNOD1DPP7ARG2 | |
| SCHEMBL4099907 | 0.87 | KMT2A (0.49) | OTCTP53SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL2237597 | 0.85 | OTC (0.59) | OTCTP53SMN1; SMN2KMT2AGSR | |
| SCHEMBL13745390 | 0.83 | MEN1 (0.61) | OTCKMT2AGSRNOD1DPP7 | |
| SCHEMBL1423420 | 0.83 | MEN1 (0.61) | OTCKMT2AGSRNOD1DPP7 | |
| SCHEMBL5946239 | 0.83 | NOD1 (0.59) | OTCHPGDGSRNOD1NOS2 | |
| SCHEMBL24692521 | 0.82 | SMN1; SMN2 (0.58) | TP53SMN1; SMN2ALDH1A1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2023288313-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20210363185-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2021-11-25 | — | — | US | disclosed |
| US-20180079783-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-9624268-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624268-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2017011820-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | disclosed |
| WO-2016011208-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| EP-2447355-A1 | MICROBIAL ACTIVITY IMPROVEMENT AGENT, MICROBIAL ACTIVITY IMPROVEMENT METHOD, AND BIOLOGICAL WASTE TREATMENT METHOD | Sumitomo Heavy Industries, LTD. (JP) | 2012-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079783-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | OTC 3996/4885TP53 2366/4885SMN1; SMN2 4421/4885 |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | OTC 4590/4885TP53 2561/4885SMN1; SMN2 4301/4885 |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | OTC 3996/4885TP53 2366/4885SMN1; SMN2 4421/4885 |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | OTC 828/4885TP53 4823/4885SMN1; SMN2 439/4885 |
| US-20220402983-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | OTC 4590/4885TP53 2561/4885SMN1; SMN2 4301/4885 |
| US-20210363185-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | OTC 2627/4885TP53 2182/4885SMN1; SMN2 4286/4885 |
| US-20180022778-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | OTC 3996/4885TP53 2366/4885SMN1; SMN2 4421/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | OTC 4590/4885TP53 2561/4885SMN1; SMN2 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.